8-K: Tenax Secures Global Oral Levosimendan Rights

Tenax Therapeutics expanded its license agreement with Orion Corporation, gaining exclusive worldwide rights for orally-administered levosimendan products and manufacturing capabilities.

Summary

• Tenax Therapeutics, Inc. (the Company) and Orion Corporation (Orion) amended their License Agreement, originally dated September 20, 2013, on September 3, 2025.
• The amendment grants Tenax exclusive worldwide rights to develop, commercialize, manufacture, and have manufactured any orally-administered pharmaceutical product containing levosimendan.
• Tenax also gained rights to manufacture or have manufactured subcutaneously administered products containing levosimendan, in addition to its existing development and commercialization rights for such products.
• Orion will supply levosimendan to Tenax for manufacturing orally-administered products for development purposes.
• The price for levosimendan supplied by Orion is in the low triple-digit thousands of Euros per kilogram.
• Payment terms for supplied levosimendan are within 45 days of invoice receipt, with invoices provided only after product delivery.
• The supplied levosimendan will conform to specified standards, be manufactured under current FDA Good Manufacturing Practices, and have a retest date no earlier than 36 months post-shipment.
• The definition of "Modified Oral Product" was updated to clarify it as any orally-administered pharmaceutical product, other than the "Oral Product," containing levosimendan.
• Orion retains all rights under its patent rights and proprietary information outside the Territory and manufacturing rights for products other than Modified Oral Products and Subcutaneously Administered Products.
• Tenax grants Orion an irrevocable, perpetual, transferable, sublicensable, fully-paid-up, non-exclusive, royalty-free right and license under Licensee Clinical Data and Licensee Grant-Back Patents for purposes not conflicting with Tenax's rights.

Sentiment

Score: 8

Explanation: The filing indicates a significant expansion of Tenax's product rights and capabilities for levosimendan, particularly with exclusive worldwide rights for oral formulations and expanded manufacturing. This is a strong positive for the company's strategic positioning and future growth potential, despite the grant-back license to Orion.

Positives

• Expanded exclusive worldwide rights for orally-administered levosimendan products, covering development, commercialization, and manufacturing.
• Gained manufacturing rights for subcutaneously administered levosimendan products, complementing existing development and commercialization rights.
• Secured a supply agreement with Orion for levosimendan API for orally-administered products, ensuring a source for development.
• The supplied levosimendan will meet FDA Good Manufacturing Practices and have a long retest date (36 months), indicating quality and stability.

Negatives

• Orion retains all rights outside the specified Territory and manufacturing rights for products other than the newly licensed Modified Oral Products and Subcutaneously Administered Products.
• Tenax grants Orion a broad, royalty-free, perpetual license to its clinical data and patents related to the product, which could limit future independent monetization of these assets outside Tenax's specific licensed rights.
• The specific price for levosimendan API, while stated as "low triple-digit thousands in Euros per kilogram," is a cost that Tenax will incur.
• The minimum order amount for levosimendan API is redacted, preventing a full assessment of potential inventory or upfront cost commitments.

Risks

• Reliance on Orion for the supply of levosimendan API for orally-administered products, which could pose supply chain risks if Orion faces production issues or delays.
• The grant-back license to Orion for Licensee Clinical Data and Licensee Grant-Back Patents means Tenax does not have exclusive control over these assets for all purposes, potentially limiting future strategic options or competitive advantage.
• The redacted minimum order amount for levosimendan API could imply a significant upfront capital commitment or inventory holding risk for Tenax.

Future Outlook

The amendment expands Tenax's product pipeline and manufacturing capabilities for levosimendan, particularly for orally-administered formulations, suggesting a strategic focus on developing and commercializing these products globally. The long retest date for supplied API supports long-term development efforts.

Industry Context

This expansion into orally-administered levosimendan products could position Tenax to address a broader patient population or different treatment settings compared to existing intravenous or subcutaneous formulations. Oral formulations often offer greater convenience and potential for chronic use, which could be a significant market advantage in the cardiovascular or critical care therapeutic areas where levosimendan is typically used. The move aligns with a broader pharmaceutical trend towards developing more patient-friendly drug delivery methods.

Stakeholder Impact

• Shareholders: Potential for increased long-term value due to expanded product pipeline, market reach, and control over manufacturing.
• Patients: Potential for new, more convenient orally-administered levosimendan treatment options.
• Employees: Potential for increased R&D and manufacturing activities, possibly leading to job growth.
• Orion Corporation: Continues to benefit from the partnership through API supply and grant-back rights.

Next Steps

• Tenax will proceed with the development and commercialization of orally-administered levosimendan products.
• Tenax will utilize its expanded manufacturing rights for both oral and subcutaneously administered levosimendan products.
• Orion will supply levosimendan API to Tenax as ordered for development purposes.

Key Dates

Recommendation

The expansion of exclusive worldwide rights for orally-administered levosimendan products, coupled with enhanced manufacturing capabilities and a secured API supply, represents a substantial strategic advancement for Tenax Therapeutics. This move significantly broadens the company's addressable market and product pipeline, offering a more convenient dosage form that could drive substantial revenue growth. While there are some restrictions, the overall impact is highly positive, suggesting strong future potential for the stock.

Keywords

Tenax Therapeutics, Orion Corporation, License Agreement, Levosimendan, Oral Drug, Subcutaneous Drug, Pharmaceutical Development, Drug Commercialization, API Supply, Biotechnology, Drug Manufacturing, SEC Filing, 8-K